青光眼治療藥的全球市場(2024年):市場分析(2023年～2029年)

本報告調查了全球青光眼治療市場，涵蓋品牌前列腺素、仿製藥前列腺素、β-阻斷劑、碳酸酐?抑製劑、α-激動劑、固定組合藥物、NO 捐贈化合物，顯示了到2029 年Rho 激?抑制劑的預測。它還廣泛討論了管道產品，涵蓋目前正在開發的 30 多種候選藥物。此外，我們還介紹了 26 家青光眼製藥公司，提供他們的產品、策略市場地位、背景和前景。

目錄

• 青光眼種類與危險因素
• 疾病診斷與治療
• 眼科醫生和含驗光師的青光眼醫療提供者的全球見解
• 全球疾病盛行率預測(5年)
• 市場上青光眼治療藥和那個作用機制
• 學名藥和品牌醫藥品的比較和對市場的影響
• 青光眼醫藥品的開發平台
• 製造·銷售青光眼治療藥的企業的簡介

What's New:

The "2024 Glaucoma Pharmaceuticals Market Report" features new regional sales forecasts that take into account appreciation of the dollar against other major currencies and an updated analysis of the prevalence and diagnosis of glaucoma that reflects COVID-19 mortality. The report now includes market share analysis of generics and branded drugs by drug class in the United States and Japan and prescription stratification by first-line and adjunctive use in the United States and Western European countries.

This new report also provides an updated analysis of the glaucoma pharma product pipeline, a summary of ongoing clinical trials, a review of Glaukos' recently approved iDose TR sustained drug delivery device, and survey data on US ophthalmologists' plans for sustained drug delivery.

The "2024 Glaucoma Pharmaceuticals Market Report" analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2029 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 26 glaucoma pharmaceutical companies are profiled, with discussion of their products, strategic market position, background, and outlook.

This report provides analysis of current markets for glaucoma medications and forecasts market performance over the next five years. The global market is analyzed based on Market Scope's eight regional/economic categories (the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World), and also uses these categories in global forecasts for disease prevalence. In addition, the report explores data and information on the disease process, glaucoma populations, glaucoma care, and a range of additional topics intended to provide depth and context to the reader's understanding of this ophthalmic segment. Coverage includes:

• Types of glaucoma and risk factors.
• Diagnosis and treatment of the disease.
• A global view of glaucoma care providers, including ophthalmologists and optometrists.
• Current estimates and five-year forecasts for disease prevalence worldwide.
• Glaucoma medications in the marketplace and their mechanisms of action.
• Discussion of generic versus branded drugs and their market impact.
• The development pipeline for glaucoma pharmaceuticals.
• Profiles of companies making and marketing glaucoma medications.

Author Profile:

Peter Downs

Peter Downs Peter Downs has more than 30 years of experience as a business and medical journalist and investigative reporter. He has written for a variety of medical industry publications, including the Medical Business Journal, CBS HealthWatch, and Oncology News International.

Prior to joining Market Scope in 2015 and turning his attention to ophthalmology, Peter analyzed markets for organ and tissue transplantation. Since joining Market Scope, he has traveled to several markets outside the US, including China, Europe, and India, to study ophthalmology at the local level.

In addition to his research and writing efforts on the ophthalmic market, he is also a contributor to Ophthalmic Market Perspectives, the firm's monthly industry newsletter.